These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 25472812

  • 1. Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014.
    Kessler C, Oldenburg J, Ettingshausen CE, Tiede A, Khair K, Négrier C, Klamroth R.
    Haemophilia; 2015 Jan; 21 Suppl 1():1-12. PubMed ID: 25472812
    [Abstract] [Full Text] [Related]

  • 2. The first recombinant FVIII produced in human cells--an update on its clinical development programme.
    Valentino LA, Negrier C, Kohla G, Tiede A, Liesner R, Hart D, Knaub S.
    Haemophilia; 2014 Jan; 20 Suppl 1():1-9. PubMed ID: 24330348
    [Abstract] [Full Text] [Related]

  • 3. PK-guided personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in adults with severe haemophilia A.
    Lissitchkov T, Rusen L, Georgiev P, Windyga J, Klamroth R, Gercheva L, Nemes L, Tiede A, Bichler J, Knaub S, Belyanskaya L, Walter O, Pasi KJ.
    Haemophilia; 2017 Sep; 23(5):697-704. PubMed ID: 28452151
    [Abstract] [Full Text] [Related]

  • 4. Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.
    Tiede A, Oldenburg J, Lissitchkov T, Knaub S, Bichler J, Manco-Johnson MJ.
    Haemophilia; 2016 May; 22(3):374-80. PubMed ID: 26582282
    [Abstract] [Full Text] [Related]

  • 5. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII.
    Sandberg H, Kannicht C, Stenlund P, Dadaian M, Oswaldsson U, Cordula C, Walter O.
    Thromb Res; 2012 Nov; 130(5):808-17. PubMed ID: 23010293
    [Abstract] [Full Text] [Related]

  • 6. Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in previously treated patients with severe haemophilia A.
    Dargaud Y, Negrier C, Rusen L, Windyga J, Georgiev P, Bichler J, Solomon C, Knaub S, Lissitchkov T, Klamroth R.
    Haemophilia; 2018 Jul; 24(4):619-627. PubMed ID: 29855112
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of Nuwiq® (human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures.
    Zozulya N, Kessler CM, Klukowska A, von Depka M, Hampton K, Hay CRM, Jansen M, Bichler J, Knaub S, Rangarajan S.
    Haemophilia; 2018 Jan; 24(1):70-76. PubMed ID: 29048712
    [Abstract] [Full Text] [Related]

  • 8. Long-term tolerability, immunogenicity and efficacy of Nuwiq® (human-cl rhFVIII) in children with severe haemophilia A.
    Klukowska A, Szczepański T, Vdovin V, Knaub S, Bichler J, Jansen M, Dzhunova I, Liesner RJ.
    Haemophilia; 2018 Jul; 24(4):595-603. PubMed ID: 29582516
    [Abstract] [Full Text] [Related]

  • 9. Development, upscaling and validation of the purification process for human-cl rhFVIII (Nuwiq®), a new generation recombinant factor VIII produced in a human cell-line.
    Winge S, Yderland L, Kannicht C, Hermans P, Adema S, Schmidt T, Gilljam G, Linhult M, Tiemeyer M, Belyanskaya L, Walter O.
    Protein Expr Purif; 2015 Nov; 115():165-75. PubMed ID: 26318235
    [Abstract] [Full Text] [Related]

  • 10. Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice.
    Vollack-Hesse N, Oleshko O, Werwitzke S, Solecka-Witulska B, Kannicht C, Tiede A.
    Blood; 2021 Feb 25; 137(8):1072-1081. PubMed ID: 32877516
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.
    Liesner RJ, Abashidze M, Aleinikova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, Guillet B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ.
    Haemophilia; 2018 Mar 25; 24(2):211-220. PubMed ID: 28815880
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
    Rea C, Dunkerley A, Sørensen B, Rangarajan S.
    Haemophilia; 2009 Nov 25; 15(6):1237-42. PubMed ID: 19664015
    [Abstract] [Full Text] [Related]

  • 13. Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq® ) in adults with severe haemophilia A: efficacy and safety.
    Lissitchkov T, Hampton K, von Depka M, Hay C, Rangarajan S, Tuddenham E, Holstein K, Huth-Kühne A, Pabinger I, Knaub S, Bichler J, Oldenburg J.
    Haemophilia; 2016 Mar 25; 22(2):225-231. PubMed ID: 26315974
    [Abstract] [Full Text] [Related]

  • 14. Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq® ) in children with severe haemophilia A: efficacy, safety and pharmacokinetics.
    Klukowska A, Szczepański T, Vdovin V, Knaub S, Jansen M, Liesner R.
    Haemophilia; 2016 Mar 25; 22(2):232-239. PubMed ID: 26370328
    [Abstract] [Full Text] [Related]

  • 15. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
    Epstein J, Xiong Y, Woo P, Li-McLeod J, Spotts G.
    Haemophilia; 2012 Mar 25; 18(2):187-92. PubMed ID: 21883704
    [Abstract] [Full Text] [Related]

  • 16. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
    Mannucci PM, Shi Q, Bonanad S, Klamroth R.
    Haemophilia; 2014 Sep 25; 20 Suppl 6():2-16. PubMed ID: 24975700
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program.
    Lissitchkov T, Klukowska A, Pasi J, Kessler CM, Klamroth R, Liesner RJ, Belyanskaya L, Walter O, Knaub S, Bichler J, Jansen M, Oldenburg J.
    Ther Adv Hematol; 2019 Sep 25; 10():2040620719858471. PubMed ID: 31263528
    [Abstract] [Full Text] [Related]

  • 18. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
    Bacon CL, Singleton E, Brady B, White B, Nolan B, Gilmore RM, Ryan C, Keohane C, Jenkins PV, O'Donnell JS.
    Haemophilia; 2011 May 25; 17(3):407-11. PubMed ID: 21382134
    [Abstract] [Full Text] [Related]

  • 19. Management of bleeding disorders: basic science.
    Ofosu FA, Santagostino E, Grancha S, Marco P.
    Haemophilia; 2012 May 25; 18 Suppl 2():8-14. PubMed ID: 22530574
    [Abstract] [Full Text] [Related]

  • 20. Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.
    Volkers P, Hanschmann KM, Calvez T, Chambost H, Collins PW, Demiguel V, Hart DP, Hay CRM, Goudemand J, Ljung R, Palmer BP, Santagostino E, van Hardeveld EM, van den Berg M, Keller-Stanislawski B.
    Haemophilia; 2019 May 25; 25(3):398-407. PubMed ID: 31066174
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.